scholarly journals Autocrine Platelet-derived Growth Factor-Vascular Endothelial Growth Factor Receptor-related (Pvr) Pathway Activity Controls Intestinal Stem Cell Proliferation in the AdultDrosophilaMidgut

2012 ◽  
Vol 287 (33) ◽  
pp. 27359-27370 ◽  
Author(s):  
David Bond ◽  
Edan Foley
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Cell Proliferation ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Intestinal Stem Cell ◽  
Vascular Endothelial ◽  
Pathway Activity ◽  
Stem Cell Proliferation ◽  
Endothelial Growth Factor

scholarly journals Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2

2008 ◽  
Vol 108 (5) ◽  
pp. 979-988 ◽  
Author(s):  
Oszkar Szentirmai ◽  
Cheryl H. Baker ◽  
Szofia S. Bullain ◽  
Ning Lin ◽  
Masaya Takahashi ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Cell Proliferation ◽  
Growth Factor ◽  
Glioblastoma Multiforme ◽  
Tumor Growth ◽  
Growth Inhibition ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Treatment Groups ◽  
Endothelial Growth Factor

Object Glioblastoma multiforme (GBM) is characterized by neovascularization, raising the question of whether angiogenic blockade may be a useful therapeutic strategy for this disease. It has been suggested, however, that, to be useful, angiogenic blockade must be persistent and at levels sufficient to overcome proangiogenic signals from tumor cells. In this report, the authors tested the hypothesis that sustained high concentrations of 2 different antiangiogenic proteins, delivered using a systemic gene therapy strategy, could inhibit the growth of established intracranial U87 human GBM xenografts in nude mice. Methods Mice harboring established U87 intracranial tumors received intravenous injections of adenoviral vectors encoding either the extracellular domain of vascular endothelial growth factor receptor-2-Fc fusion protein (Ad-VEGFR2-Fc) alone, soluble endostatin (Ad-ES) alone, a combination of Ad-VEGFR2-Fc and Ad-ES, or immunoglobulin 1-Fc (Ad-Fc) as a control. Results Three weeks after treatment, magnetic resonance imaging-based determination of tumor volume showed that treatment with Ad-VEGFR2-Fc, Ad-ES, or Ad-VEGFR2-Fc in combination with Ad-ES, produced 69, 59, and 74% growth inhibition, respectively. Bioluminescent monitoring of tumor growth revealed growth inhibition in the same treatment groups to be 62, 74, and 72%, respectively. Staining with proliferating cell nuclear antigen and with terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling showed reduced tumor cell proliferation and increased apoptosis in all antiangiogenic treatment groups. Conclusions These results suggest that systemic delivery and sustained production of endostatin and soluble VEGFR2 can slow intracranial glial tumor growth by both reducing cell proliferation and increasing tumor apoptosis. This work adds further support to the concept of using antiangiogenesis therapy for intracranial GBM.

scholarly journals Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia

2018 ◽  
Vol 24 (7) ◽  
pp. 1056-1060 ◽  
Author(s):  
Grażyna Gadomska ◽  
Alicja Bartoszewska-Kubiak ◽  
Joanna Boinska ◽  
Karolina Matiakowska ◽  
Katarzyna Ziołkowska ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Essential Thrombocythemia ◽  
Leukemia Virus ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Vascular Endothelial ◽  
High Concentration ◽  
Endothelial Growth Factor ◽  
Calr Mutation

The aim of the study was to evaluate selected angiogenic factors in patients with essential thrombocythemia (ET) depending on JAK2V617F, calreticulin gene (CALR) and myeloproliferative leukemia virus oncogene (MPL) mutations. Sixty ET patients and 20 healthy volunteers were enrolled in the study. The following tests were performed: vascular endothelial growth factor- A (VEGF-A), soluble vascular endothelial growth factor receptor-1 (sVEGFR-1),soluble vascular endothelial growth factor receptor-2 (sVEGFR-2), platelet-derived growth factor( PDGF-BB), and stromal-derived factor-1α (SDF-1α). We observed an increased PDGF-BB level in patients with ET compared to the controls. Patients with CALR mutation had significantly higher concentration of PDGF-BB and lower concentration of SDF-1α than patients with JAK2V617F mutation. High concentration of PDGF-BB and low concentration of SDF-1α in patients with CALR(+) ET may indicate a contribution of these chemokines in disturbed Ca2+ metabolism in platelets.

Die Häufigkeit von Anti-VEGF-A-Injektionen und Ödemrezidiven hängt vom Grad der begleitenden lokalen zellulären Entzündung ab

2017 ◽  
Vol 3 (2) ◽  
pp. 70-71
Author(s):  
Olaf Strauss
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Adhesion Molecule ◽  
Growth Factor Receptor ◽  
Platelet Derived Growth Factor ◽  
Intercellular Adhesion Molecule ◽  
Vascular Endothelial ◽  
Intercellular Adhesion Molecule 1 ◽  
Endothelial Growth Factor ◽  
Zentrale Netzhautdicke

Wir maßen die Konzentrationen von Zytokinen und Wachstums-/Entzündungsfaktoren im Kammerwasser von 46 Patienten mit retinalem Venenastverschluss (VAV) und Makulaödem (MÖ), die mit einer intravitrealen Ranibizumab-Injektion (IRI) behandelt wurden. Patienten mit rezidivierendem MÖ erhielten bei Bedarf eine weitere IRI. Die Anzahl der IRI-Behandlungen korrelierte signifikant mit dem Alter, dem Visus c.c. bei Studienbeginn, der zentralen Netzhautdicke bei Studienbeginn sowie den Konzentrationen von 5 Zytokinen/Faktoren im Kammerwasser bei Studienbeginn (löslicher VEGFR-1 (vascular endothelial growth factor receptor 1), PDGF-AA (platelet-derived growth factor-AA), lösliches ICAM-1 (intercellular adhesion molecule 1), IL-6 (Interleukin 6) und IL-8). Die multivariate lineare Regressionsanalyse mit schrittweiser Auswahl bestätigte, dass Alter, zentrale Netzhautdicke bei Studienbeginn und PDGF-AA-Wert bei Studienbeginn unabhängige Determinanten der Anzahl der IRI-Behandlungen waren. Diese Ergebnisse deuten darauf hin, dass Entzündungsfaktoren möglicherweise das erneute Auftreten von MÖ bei VAV-Patienten beeinflussen können und dass der PDGF-AA-Wert ein hilfreicher Indikator dafür sein könnte, wie viele IRI-Behandlungen für die Beherrschung des MÖ erforderlich sein werden.

Sign in / Sign up

Export Citation Format

Share Document